Literature DB >> 34001753

Theoretical Framework for Retrospective Studies of the Effectiveness of SARS-CoV-2 Vaccines.

Joseph A Lewnard1,2,3, Manish M Patel4, Nicholas P Jewell5,6, Jennifer R Verani4, Miwako Kobayashi4, Mark W Tenforde4, Natalie E Dean7, Benjamin J Cowling8, Benjamin A Lopman9.   

Abstract

Observational studies of the effectiveness of vaccines to prevent COVID-19 are needed to inform real-world use. Such studies are now underway amid the ongoing rollout of SARS-CoV-2 vaccines globally. Although traditional case-control and test-negative design studies feature prominently among strategies used to assess vaccine effectiveness, such studies may encounter important threats to validity. Here, we review the theoretical basis for estimation of vaccine direct effects under traditional case-control and test-negative design frameworks, addressing specific natural history parameters of SARS-CoV-2 infection and COVID-19 relevant to these designs. Bias may be introduced by misclassification of cases and controls, particularly when clinical case criteria include common, nonspecific indicators of COVID-19. When using diagnostic assays with high analytical sensitivity for SARS-CoV-2 detection, individuals testing positive may be counted as cases even if their symptoms are due to other causes. The traditional case-control design may be particularly prone to confounding due to associations of vaccination with healthcare-seeking behavior or risk of infection. The test-negative design reduces but may not eliminate this confounding, for instance, if individuals who receive vaccination seek care or testing for less-severe illness. These circumstances indicate the two study designs cannot be applied naively to datasets gathered through public health surveillance or administrative sources. We suggest practical strategies to reduce bias in vaccine effectiveness estimates at the study design and analysis stages.
Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 34001753      PMCID: PMC8168935          DOI: 10.1097/EDE.0000000000001366

Source DB:  PubMed          Journal:  Epidemiology        ISSN: 1044-3983            Impact factor:   4.822


  25 in total

1.  Odds of Testing Positive for SARS-CoV-2 Following Receipt of 3 vs 2 Doses of the BNT162b2 mRNA Vaccine.

Authors:  Tal Patalon; Sivan Gazit; Virginia E Pitzer; Ottavia Prunas; Joshua L Warren; Daniel M Weinberger
Journal:  JAMA Intern Med       Date:  2022-02-01       Impact factor: 44.409

2.  Effectiveness of the CoronaVac vaccine in older adults during a gamma variant associated epidemic of covid-19 in Brazil: test negative case-control study.

Authors:  Otavio T Ranzani; Matt D T Hitchings; Murilo Dorion; Tatiana Lang D'Agostini; Regiane Cardoso de Paula; Olivia Ferreira Pereira de Paula; Edlaine Faria de Moura Villela; Mario Sergio Scaramuzzini Torres; Silvano Barbosa de Oliveira; Wade Schulz; Maria Almiron; Rodrigo Said; Roberto Dias de Oliveira; Patricia Vieira da Silva; Wildo Navegantes de Araújo; Jean Carlo Gorinchteyn; Jason R Andrews; Derek A T Cummings; Albert I Ko; Julio Croda
Journal:  BMJ       Date:  2021-08-20

3.  On the role of statisticians and modelers in responding to AIDS and COVID-19.

Authors:  Britta L Jewell; Nicholas P Jewell
Journal:  Stat Med       Date:  2021-05-20       Impact factor: 2.373

4.  Effectiveness of BNT162b2 Vaccine against Critical Covid-19 in Adolescents.

Authors:  Samantha M Olson; Margaret M Newhams; Natasha B Halasa; Ashley M Price; Julie A Boom; Leila C Sahni; Pia S Pannaraj; Katherine Irby; Tracie C Walker; Stephanie P Schwartz; Aline B Maddux; Elizabeth H Mack; Tamara T Bradford; Jennifer E Schuster; Ryan A Nofziger; Melissa A Cameron; Kathleen Chiotos; Melissa L Cullimore; Shira J Gertz; Emily R Levy; Michele Kong; Natalie Z Cvijanovich; Mary A Staat; Satoshi Kamidani; Brandon M Chatani; Samina S Bhumbra; Katherine E Bline; Mary G Gaspers; Charlotte V Hobbs; Sabrina M Heidemann; Mia Maamari; Heidi R Flori; Janet R Hume; Matt S Zinter; Kelly N Michelson; Laura D Zambrano; Angela P Campbell; Manish M Patel; Adrienne G Randolph
Journal:  N Engl J Med       Date:  2022-01-12       Impact factor: 176.079

5.  Effectiveness of mRNA-1273 against delta, mu, and other emerging variants of SARS-CoV-2: test negative case-control study.

Authors:  Katia J Bruxvoort; Lina S Sy; Lei Qian; Bradley K Ackerson; Yi Luo; Gina S Lee; Yun Tian; Ana Florea; Michael Aragones; Julia E Tubert; Harpreet S Takhar; Jennifer H Ku; Yamuna D Paila; Carla A Talarico; Hung Fu Tseng
Journal:  BMJ       Date:  2021-12-15

6.  Effectiveness of ChAdOx1 vaccine in older adults during SARS-CoV-2 Gamma variant circulation in São Paulo.

Authors:  Matt D T Hitchings; Otavio T Ranzani; Murilo Dorion; Tatiana Lang D'Agostini; Regiane Cardoso de Paula; Olivia Ferreira Pereira de Paula; Edlaine Faria de Moura Villela; Mario Sergio Scaramuzzini Torres; Silvano Barbosa de Oliveira; Wade Schulz; Maria Almiron; Rodrigo Said; Roberto Dias de Oliveira; Patricia Vieira Silva; Wildo Navegantes de Araújo; Jean Carlo Gorinchteyn; Jason R Andrews; Derek A T Cummings; Albert I Ko; Julio Croda
Journal:  Nat Commun       Date:  2021-10-28       Impact factor: 14.919

7.  Effectiveness of COVID-19 vaccines in preventing SARS-CoV-2 infection and hospitalisation, Navarre, Spain, January to April 2021.

Authors:  Iván Martínez-Baz; Ana Miqueleiz; Itziar Casado; Ana Navascués; Camino Trobajo-Sanmartín; Cristina Burgui; Marcela Guevara; Carmen Ezpeleta; Jesús Castilla
Journal:  Euro Surveill       Date:  2021-05

8.  Effectiveness of SARS-CoV-2 mRNA Vaccines for Preventing Covid-19 Hospitalizations in the United States.

Authors:  Jennifer R Verani; Wesley H Self; Mark W Tenforde; Manish M Patel; Adit A Ginde; David J Douin; H Keipp Talbot; Jonathan D Casey; Nicholas M Mohr; Anne Zepeski; Manjusha Gaglani; Tresa McNeal; Shekhar Ghamande; Nathan I Shapiro; Kevin W Gibbs; D Clark Files; David N Hager; Arber Shehu; Matthew E Prekker; Heidi L Erickson; Matthew C Exline; Michelle N Gong; Amira Mohamed; Daniel J Henning; Jay S Steingrub; Ithan D Peltan; Samuel M Brown; Emily T Martin; Arnold S Monto; Akram Khan; C Terri Hough; Laurence Busse; Caitlin C Ten Lohuis; Abhijit Duggal; Jennifer G Wilson; Alexandra June Gordon; Nida Qadir; Steven Y Chang; Christopher Mallow; Hayley B Gershengorn; Hilary M Babcock; Jennie H Kwon; Natasha Halasa; James D Chappell; Adam S Lauring; Carlos G Grijalva; Todd W Rice; Ian D Jones; William B Stubblefield; Adrienne Baughman; Kelsey N Womack; Christopher J Lindsell; Kimberly W Hart; Yuwei Zhu; Samantha M Olson; Meagan Stephenson; Stephanie J Schrag; Miwako Kobayashi
Journal:  medRxiv       Date:  2021-07-08

9.  Effectiveness of CoronaVac among healthcare workers in the setting of high SARS-CoV-2 Gamma variant transmission in Manaus, Brazil: A test-negative case-control study.

Authors:  Matt D T Hitchings; Otavio T Ranzani; Mario Sergio Scaramuzzini Torres; Silvano Barbosa de Oliveira; Maria Almiron; Rodrigo Said; Ryan Borg; Wade L Schulz; Roberto Dias de Oliveira; Patricia Vieira da Silva; Daniel Barros de Castro; Vanderson de Souza Sampaio; Bernardino Cláudio de Albuquerque; Tatyana Costa Amorim Ramos; Shadia Hussami Hauache Fraxe; Cristiano Fernandes da Costa; Felipe Gomes Naveca; Andre M Siqueira; Wildo Navegantes de Araújo; Jason R Andrews; Derek A T Cummings; Albert I Ko; Julio Croda
Journal:  Lancet Reg Health Am       Date:  2021-07-25

10.  Prevention of Coronavirus Disease 2019 (COVID-19) by mRNA-Based Vaccines Within the General Population of California.

Authors:  Kristin L Andrejko; Jake Pry; Jennifer F Myers; Nicholas P Jewell; John Openshaw; James Watt; Seema Jain; Joseph A Lewnard
Journal:  Clin Infect Dis       Date:  2022-04-28       Impact factor: 20.999

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.